News

  • FDA approves Vosevi for Hepatitis C
    Post time: Nov-24-2017

    The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir...Read more »

  • Post time: Nov-24-2017

    API China, taking place from 16-18 May 2017 in Shanghai, China Read more »

  • Post time: Nov-24-2017

    API China, taking place from 16-18 November 2016 in Wuhan,China Read more »

  • Post time: Nov-24-2017

    CPhI China, taking place from 20-22 June 2017 at SNIEC, Shanghai, China Read more »

  • Post time: Nov-24-2017

    CPhI India 2016 Read more »

  • Post time: Nov-24-2017

    Eleven medicines leap towards EU approval 2016-09-21 15:27:20 Eleven new medicines have taken a giant leap closer to European Union approval after having won the backing of the Committee for Medicinal Products for Human Use. The Committee has put forward three new drugs for the treatment of canc...Read more »

  • Post time: Nov-24-2017

    75 percent higher proportion of relapsing multiple sclerosis (RMS) patients achieved No Evidence of Disease Activity (NEDA) with OCREVUS compared with interferon beta-1a (Rebif ®) 47 percent higher proportion of primary progressive multiple sclerosis (PPMS) patients achieved No Evidence of Progre...Read more »

  • Post time: Nov-24-2017

    Berlin, September 19, 2016 – The U.S. Food and Drug Administration (FDA) has approved Bayer AG’s new low dose levonorgestrel-releasing intrauterine system (LNG-IUS) which will be marketed in the US under the brand name Kyleena™. Kyleena releases the lowest daily dose of the hormone levonorgestrel...Read more »

WhatsApp Online Chat !